BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38071551)

  • 1. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
    Li Y; Kazuki Y; Drabison T; Kobayashi K; Fujita KI; Xu Y; Jin Y; Ahmed E; Li J; Eisenmann ED; Baker SD; Cavaletti G; Sparreboom A; Hu S
    Drug Metab Dispos; 2024 Jan; 52(2):80-85. PubMed ID: 38071551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
    Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
    Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
    Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
    Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
    Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
    Sims RP
    J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
    Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
    Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
    Dennison JB; Jones DR; Renbarger JL; Hall SD
    J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
    Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
    J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
    Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
    J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cytochrome P450 3A5 genotype on early tacrolimus metabolism and clinical outcomes in lung transplant recipients.
    Du W; Wang X; Zhang D; Chen W; Zhang X; Li P
    Int J Clin Pharm; 2022 Apr; 44(2):418-427. PubMed ID: 34859357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
    Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
    Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
    Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
    Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
    Saba N; Seal A
    J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective metabolism of vincristine in vitro by CYP3A5.
    Dennison JB; Kulanthaivel P; Barbuch RJ; Renbarger JL; Ehlhardt WJ; Hall SD
    Drug Metab Dispos; 2006 Aug; 34(8):1317-27. PubMed ID: 16679390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo.
    Uehara S; Shimizu M; Plé K; Routier S; Yoneda N; Higuchi Y; Suemizu H; Yamazaki H
    Drug Metab Pharmacokinet; 2022 Jun; 44():100453. PubMed ID: 35381575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.
    Abe S; Kobayashi K; Oji A; Sakuma T; Kazuki K; Takehara S; Nakamura K; Okada A; Tsukazaki Y; Senda N; Honma K; Yamamoto T; Ikawa M; Chiba K; Oshimura M; Kazuki Y
    Sci Rep; 2017 Nov; 7(1):15189. PubMed ID: 29123154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.